However, for the high-risk prostate cancer patients, accounting for 15% of all prostate cancer, 30–60% of them would develop biochemical recurrence (BCR), flare up of PSA, at around 10 years [2], followed by the clinical metastasis months to years later [3]. Here, KLK3 is linked to prostate carcinoma.